ORION OYJ |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.61 EUR | -0.05% |
|
+4.87% | +5.78% |
| 07-01 | Orion, Merck & Co. Convert Agreement into Exclusive Global License to Opevesostat | MT |
| 07-01 | Orion Upgrades FY24 Outlook After Modifying Agreement with Merck & Co | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows:
- generic, OTC and biosimilar drugs (43.4%);
- patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments;
- animal health products (8.7%);
- pharmaceutical ingredients and outsourcing services (6.2%).
Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%).
Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).
Sector
Pharmaceuticals
Calendar
08/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
41.63
EUR
Average target price
38.6
EUR
Spread / Average Target
-7.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.78% | 6.27B | |
| +55.70% | 816B | |
| +39.44% | 634B | |
| -7.50% | 351B | |
| +16.67% | 323B | |
| +7.49% | 293B | |
| +13.14% | 238B | |
| +0.78% | 222B | |
| +13.39% | 218B | |
| +8.23% | 167B |
- Stock Market
- Equities
- ORNBV Stock
- News Orion Oyj
- Orion, Merck & Co. Convert Agreement into Exclusive Global License to Opevesostat
